[Development of a method for the assessment of melamine in urines by GC-MS/MS. An attempt to define a reference value]. / Messa a punto di un metodo di valutazione della melamina su urine in GC-MSMS. Un tentativo di definizione di un valore di riferimento.

Melamine is used in the synthesis of resins used for the manufacture of laminates, plastics and coatings, including materials in contact with food such as crockery. A method for the assessment of melamine by GC-MSMS in urine samples was developed and tested in 100 non-occupationally exposed subjects: 63 females (14-66) and 37 males (15-65). The LOD and LOQ were 4 microg/l and 13.4 microg/l respectively. Results showed traces of melamine in the urines of 21% of subjects monitored (10-29.7 microg/l). Presence of melamine and time since last meal at sampling were inversely related (p = 0.021). In addition a significant correlation (p = 0.00) between the presence of the substance in urines and the use of melamine dishes was shown.

[Aromatic amines with certain, probable, or possible carcinogenic action: reference values]. / Ammine aromatiche ad azione cancerogena certa, probabile o possibile: valori di riferimento.

The aim of this work is to determine the amount of some aromatic amines in urine of non-exposed people in order to define a reference value. The literature examination has showed that only a small numbers of aromatic amines are usually determined in urine namely: aniline, benzidine, 2-naphtilamine, o-toluidine, 3,3'-dichlorobenzidine, 4-chloro-o-toluidine and 4-chlorobenzidine. On the basis of our experience the analytical method proposed by Lichtenstein is appropriate for obtaining reliable analytical results.

Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients.

BACKGROUND: In an attempt to find new parameters able to evaluate the actual iron availability by bone marrow cells, zinc protoporphyrin (ZnPP), a metabolic intermediate generated in the red blood cell by the incorporation of zinc instead of iron, has been proposed. ZnPP is a good marker of iron-deficiency anemia in non-uremic people, as red blood cell ZnPP concentration rises specifically (except for lead intoxication) in this condition. Existing data on ZnPP as a marker of iron deficiency in uremic patients comes mainly from cross sectional studies on chronic hemodialysis and has produced conflicting results. SUBJECTS AND METHODS: Therefore, we prospectively studied 42 HID patients, 28-88 years old, 13-346 months of dialysis age, beginning from a period of maximal iron deficiency, due to the lack of parenteral iron compounds (T0) up to the end of more than one year of follow-up with continuous parenteral iron supplementation (T4). ZnPP, hemoglobin, transferrin saturation and ferritin were serially determined before and after six weeks (T1), four months (T2), seven months (T3) and 14 months (T4) of parenteral iron supplementation at a maintenance dose of 0.5-1 mg/kg/week. RESULTS: In comparison with baseline values (95+/-37 micromol/mol heme) there were no significant changes in ZnPP levels at T1 and T2 despite a continuous increase in both transferrin saturation and ferritin values, while ZnPP significantly decreased at T4 (63+/-37 micromol/mol heme, p<0.001). There was no correlation between ZnPP and both transferrin saturation and ferritin at any time during the study, the same was true for ZnPP and zinc and lead serum concentration, fibrinogen and reactive C protein levels at T1 and T4, respectively. At T4, only 2/10 patients who still showed ZnPP levels >80 micromol/mol heme had absolute or functional iron deficiency, when the percentage of hypochromic red cells were measured. CONCLUSION: We conclude that ZnPP untimely parallels a change in iron balance in only a proportion of uremic people, in as much as confounding factors, such as chronic inflammation and uremia in itself may obscure its relationship with iron status. Therefore, ZnPP cannot be assumed to be a first-line diagnostic marker of iron balance in uremic patients.

Monitoring propofol serum levels by rapid and sensitive reversed-phase high-performance liquid chromatography during prolonged sedation in ICU patients.

A quick and sensitive reversed-phase high-performance liquid chromatography (HPLC) method has been developed in order to determine the concentration of Propofol (2,6 diisopropylphenol) in human serum. Propofol can be isolated from serum by adding 0.5 mL precipitating solution. This consists of an acetonitrile and perchloric acid (67:33, v/v) mixture, which also contains dibutylphthalate (2 mg/100 mL) as internal standard. The sample is then mixed for 1 min on a vortex-mixer. The endogenous serum substances precipitated by acetonitrile and perchloric acid are further separated by centrifugation. The supernatant is directly injected into the HPLC system. A 250- x 4.6-mm column, packed with 10-microns Spherisorb reversed-phase octadecylsilane particles (C18), is used for chromatographic separation. The mobile phase consists of an acetonitrile-water mixture (67:33 ratio) with 0.4 mL acetic acid (pH 4). Propofol is monitored by a UV-visible detector at 270 nm and 0.1-0.002 absorbance units full scale (AUFS). The detection limit of Propofol (in human serum) is 0.1 mg/L for a 20-microL injection volume. The time of the assay is less than 20 min, including sample preparation.

Excretion kinetics of the rubber anti-oxidant N-isopropyl-N'-phenyl-p-phenylendiamine (IPPD).

Sixteen rubber vulcanizers using IPPD as anti-oxidant were monitored for the presence of the parent compound in the urine during two consecutive working weeks using HPLC for analysis. At least two components in the excretion kinetics could be demonstrated: a fast one, as end-shift urinary concentrations significantly exceeded before-shift ones, and a less rapid one, as before-shift values at the end of the week significantly differed from those determined at the beginning. A skin absorption experiment was also performed. It demonstrated three components in the excretion kinetics, with apparent half-times of approximately 3, 7 and 24 h. Excretion ceased 7 d after skin exposure.